World Stem Cells & Regenerative Medicine Congress Asia 2009

It has been 10 years since embryonic stem cells were first isolated. There was tremendous optimism of new cures, but that faded as the Bush administration put more and more obstacles in the way of stem cell research. Now Bush is gone, Obama’s in, and hopes and expectations are rising again. In the beginning of 2009, the FDA approved the fi rst trials of embryonic stem cell therapy for human patients — paralyzed patients with spinal cord injuries. We are on the cusp of a worldwide explosion of activity in this rapidly growing field of biomedicine that will revolutionize healthcare treatment. Because of the economic potential of this industry, initiatives to capture significant shares of this market are multiplying around the world and competition is mounting.

In contrast to their western counterparts, Asian scientists conducting stem cell research face fewer restrictions, and have the full support and encouragement of their governments. However, despite the favourable regulatory landscape and advances in stem cell research, Asia has been lagging in areas of clinical translation and commercialization.

World Stem cells and Regenerative Medicine Congress Asia 2009 will bridge these gaps by bringing together stem cell companies, academics and clinicians from all over Asia-Pacifi c. So, come and experience the energy. Meet the key players in industry as well as academia and share your expertise and know-how.

Подробнее о конференции ( pdf 1.38 Мб)